Following on from information provided to NICE by the company in March 2020, the appraisal of Etirinotecan pegol for treating breast cancer with brain metastases [ID881] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 881
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 November 2022 | Discontinued. Following on from information provided to NICE by the company in March 2020, the appraisal of Etirinotecan pegol for treating breast cancer with brain metastases [ID881] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 21 April 2020 | Note added to the project documents |
| 25 July 2017 | Suspended. The Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for etirinotecan pegol intended for the treatment of advanced breast cancer with brain metastases. Consequently the first appraisal committee discussion of this topic, has been cancelled. We will continue to monitor any developments and will update interested parties if the situation changes. |
| 18 August 2016 | Invitation to participate |
| 02 June 2016 | Draft scope documents |
| 13 May 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual